| Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci EA Stahl, S Raychaudhuri, EF Remmers, G Xie, S Eyre, BP Thomson, Y Li, ... Nature genetics 42 (6), 508-514, 2010 | 1619 | 2010 |
| C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? WK Lagrand, CA Visser, WT Hermens, HWM Niessen, FWA Verheugt, ... Circulation 100 (1), 96-102, 1999 | 1502 | 1999 |
| Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up GM Bartelds, CLM Krieckaert, MT Nurmohamed, PA van Schouwenburg, ... Jama 305 (14), 1460-1468, 2011 | 960 | 2011 |
| Adalimumab with or without methotrexate in juvenile rheumatoid arthritis DJ Lovell, N Ruperto, S Goodman, A Reiff, L Jung, K Jarosova, ... New England Journal of Medicine 359 (8), 810-820, 2008 | 792 | 2008 |
| Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis GM Bartelds, CA Wijbrandts, MT Nurmohamed, S Stapel, WF Lems, ... Annals of the rheumatic diseases 66 (7), 921-926, 2007 | 740 | 2007 |
| Rituximab treatment in patients with primary Sjögren's syndrome: an open‐label phase II study J Pijpe, GW Van Imhoff, FKL Spijkervet, JLN Roodenburg, GJ Wolbink, ... Arthritis & Rheumatism 52 (9), 2740-2750, 2005 | 641 | 2005 |
| Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis GJ Wolbink, M Vis, W Lems, AE Voskuyl, E De Groot, MT Nurmohamed, ... Arthritis & Rheumatism 54 (3), 711-715, 2006 | 625 | 2006 |
| Common variants at CD40 and other loci confer risk of rheumatoid arthritis S Raychaudhuri, EF Remmers, AT Lee, R Hackett, C Guiducci, NP Burtt, ... Nature genetics 40 (10), 1216-1223, 2008 | 618 | 2008 |
| C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction WK Lagrand, HWM Niessen, GJ Wolbink, LH Jaspars, CA Visser, ... Circulation 95 (1), 97-103, 1997 | 592 | 1997 |
| Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis PA Van Schouwenburg, T Rispens, GJ Wolbink Nature Reviews Rheumatology 9 (3), 164-172, 2013 | 534 | 2013 |
| Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk S Raychaudhuri, BP Thomson, EF Remmers, S Eyre, A Hinks, C Guiducci, ... Nature genetics 41 (12), 1313-1318, 2009 | 405 | 2009 |
| Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study WH Bos, GJ Wolbink, M Boers, GJ Tijhuis, N de Vries, ... Annals of the rheumatic diseases 69 (3), 490-494, 2010 | 374 | 2010 |
| Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity MD Larsen, EL de Graaf, ME Sonneveld, HR Plomp, J Nouta, W Hoepel, ... Science 371 (6532), eabc8378, 2021 | 365 | 2021 |
| CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. GJ Wolbink, MC Brouwer, S Buysmann, IJ Ten Berge, CE Hack Journal of immunology (Baltimore, Md.: 1950) 157 (1), 473-479, 1996 | 337 | 1996 |
| Inhibition of human complement by β‐glycyrrhetinic acid BH Kroes, CJ Beukelman, AJJ Van Den Berg, GJ Wolbink, H Van Dijk, ... Immunology 90 (1), 115-120, 1997 | 319 | 1997 |
| Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study GM Bartelds, CA Wijbrandts, MT Nurmohamed, S Stapel, WF Lems, ... Annals of the rheumatic diseases 69 (5), 817-821, 2010 | 305 | 2010 |
| Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner CL Krieckaert, MT Nurmohamed, GJ Wolbink Annals of the rheumatic diseases 71 (11), 1914-1915, 2012 | 303 | 2012 |
| Development of the anti–citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis LA van de Stadt, MHMT de Koning, RJ van de Stadt, G Wolbink, ... Arthritis & Rheumatism 63 (11), 3226-3233, 2011 | 296 | 2011 |
| All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists L Carmona, MA Descalzo, E Perez-Pampin, D Ruiz-Montesinos, A Erra, ... Annals of the rheumatic diseases 66 (7), 880-885, 2007 | 293 | 2007 |
| Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis GJ Wolbink, AE Voskuyl, WF Lems, E De Groot, MT Nurmohamed, PP Tak, ... Annals of the rheumatic diseases 64 (5), 704-707, 2005 | 283 | 2005 |
Theo RispensSanquin ResearchAdresse e-mail validée de sanquin.nl